Alicia Granados, MD, PhD

Dr. Alicia Granados is a board-certified specialist in respiratory medicine and holds a PhD in Public Health from the University of Barcelona, where she served as Associate Professor of Medicine with a focus on Health Technology Assessment (HTA) Science and Evidence-Based Health Care. Dr. Granados currently serves as Global Head of Scientific Advocacy and Insights within Global Medical Affairs for Rare Disorders at Sanofi. In this role, she champions the development of more integrative evidence frameworks for rare diseases, with a particular focus on operationalizing the concept of "totality of evidence" to more comprehensively capture the full spectrum of intervention effects in rare disease settings. Prior to this position, she led Global HTA Strategy at Sanofi from 2011 to 2021. Dr. Granados plays a leading role in several Innovative Medicines Initiative (IMI) and Innovative Health Initiative (IHI) projects, including Screen4Care, Together4Rare, and ReaiseD, all of which aim to advance both evidence generation and evidence interpretation in rare disorders. A recognized leader in the HTA field, Dr. Granados was the Founder and first President of the International Society for Health Technology Assessment (HTAi) and a founding member of the International Network of Agencies for Health Technology Assessment (INAHTA). She currently serves as co-Chair of the HTAi Rare Diseases Interest Group. Dr. Granados has advised multiple United Nations agencies on Evidence-Based Health Care and previously served as Acting Regional Advisor at the WHO European Office. She is the author of more than 70 scientific and policy publications spanning respiratory medicine, health technology assessment, and rare disorders.